Medco Commits $20 Mil. To Part D Development, Implementation Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
Capital investment will be used to develop the infrastructure required to participate in the Medicare prescription drug program, including software programs and communication materials.
You may also be interested in...
Medco Creates Largest U.S. Specialty Pharmacy Through Accredo Acquisition
The companies' combined specialty drug sales were about $4.3 bil. in 2004. The acquisition puts Medco in a position to take a large share of Medicare Part B drug business in addition to its stake in the Part D outpatient drug benefit.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.